TheImmunityBio COVID-19 vaccine, codenamedhAd5, is anon replicating viral vector[1]COVID-19 vaccine developed by the United States-based pharmaceutical companyImmunityBio.[2][1]
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Viral vector |
| Clinical data | |
| Trade names | hAd5 |
| Identifiers | |
| CAS Number | |
The BioVac Institute, a state-backedSouth African vaccine company, plans to use a deal it won to manufacturecoronavirus vaccines. The contract withAmerica-based ImmunityBio Inc is currently conducting phase 1 vaccine trials inSouth Africa[3]
ImmunityBio andBioVac plan to distribute the vaccines throughoutSouth Africa and Africa.[4][5]
In April 2020, a product developed by ImmunityBio was rumoured to be a potentialSARS-CoV-2 coronavirus vaccine.[6]
On 1 June 2020, the product was selected for inclusion on theOperation Warp Speed subsidy list, in order to fund monkey trials.[7] The company "hope to receive approval from theFood and Drug Administration to begin an initial safety trial in humans in June 2020."[7]
ImmunityBio Inc is currently conducting phase 1 vaccine trials in TheUnited States andSouth Africa.[3][8][9][needs update]
| Development | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Classes | |||||||||||
| Administration | |||||||||||
| Vaccines |
| ||||||||||
| Inventors/ researchers | |||||||||||
| Controversy | |||||||||||
| Related | |||||||||||
| |||||||||||
.svg)